The virus is the delivery van. The cargo is the patent estate.
KaliVir Immunotherapeutics holds 11 patent families: 3 granted and 8 published and pending. Filing began in 2018, with the most recent published filing dated 2023-12-14. The families appear in 7 patent offices: Australia, Canada, Europe, Israel and South Korea.Patent figures from Google Patents Public Data, reviewed 2026-09-14. Funding: $14M Series A, Flexus Partners, Premier Partners and Nextrans, 2026-08-19.
KaliVir Immunotherapeutics closed a $14M Series A on eleven patent families first filed in 2018. The company describes itself as an oncolytic virus developer. The claim titles describe something narrower and more interesting: what the virus is engineered to carry, and who thought of it first.
Fourteen million, six years after the first filing
The Series A came from Flexus Partners, Premier Partners and Nextrans. Fourteen million dollars into a company founded in 2019. That is the visible event. The invisible one happened first: the earliest priority date in the portfolio is 2018, before the company legally existed. Somebody was filing on this before there was an entity to assign it to.
That gap matters more than the dollar figure. A Series A priced against eleven families with a 2018 anchor is a different instrument from one priced against a deck. The last public filing is dated 14 December 2023, thirty-two months before this round. Whatever was filed in the run-up to the raise has not surfaced yet. It would not have.
Three solid ticks, eight thin ones
Eleven families. Three granted and enforceable today. Eight published and pending, with the first of those close enough to grant that the arc could change shape without warning. Filings run AU, CA, EP, IL, KR, TW and WO, which is a deliberate spread rather than a US-plus-Europe reflex. Taiwan and Israel in particular are choices, not defaults.
The velocity tells its own story. One family in 2018, one in 2019, three in 2020, one in 2021, two in 2022, three in 2023. No single burst. A steady drip across six years, with the heaviest years bracketing the middle and the end. This is a portfolio built by people returning to the same problem, not one assembled to support a fundraise.
Three of eleven are granted, which means three of eleven are real today rather than probable.
One name on nine of eleven families
Twenty inventors are named across the estate. That is a wide bench for eleven families. But the distribution is not flat. Mingrui Zhang appears on nine of the eleven, and the name also appears as Ming-Rui Zhang on six records, which suggests the concentration is at least that high and possibly higher. Stephen Howard Thorne is on six.
Two dense nodes, eighteen contributors around them. Portfolios shaped this way are usually the product of a continuing research programme rather than a series of separate bets. The recent titles support that reading: CD47 and SIRP-alpha checkpoint inhibitors, nucleic acids encoding a TGF-beta inhibitor with IL-12, nucleic acids encoding soluble PD-1 with IL-12. Variations on one idea, paid out over years.
Eleven families against six hundred
The same CPC groups, medicinal preparations under A61K and genetic engineering under C12N, have drawn University of California with 611 families over five years. Jiangnan University filed 432. Zhejiang University 328, Huazhong Agricultural University 325, China Agricultural University 312, Leland Stanford Junior University 280. KaliVir sits at eleven. On this scale it is a dot beside discs.
Volume in these classes is not the same as overlap. A61K and C12N are enormous tents that cover most of modern biologics. What separates an eleven-family estate from a six-hundred-family one is not count but where the claims land. The recent titles are specific to particular payload combinations delivered by particular means. Specificity is the only defence available at this size, and it is a real one.
Pfizer and Genelux reading the same file
Five organisations cite back into this portfolio. Zhengzhou University three times. Calidi Biotherapeutics Nevada three. Pfizer twice. Genelux twice. Caliver Immunotherapeutics twice. Two of those are oncolytic virus specialists, one is among the largest pharmaceutical companies in the world, and two are academic or adjacent.
Citations of this kind are a form of acknowledgement. Examiners and applicants working in adjacent territory have found this small estate relevant enough to place on the record. For an eleven-family portfolio sitting inside CPC groups dominated by institutions with hundreds of filings, being cited by Pfizer and Genelux is the clearest external signal available that the claims occupy ground others are walking through.
Small portfolios become visible when larger ones have to cite them.
What the next two years will show
Here is the plain version. KaliVir describes itself as an oncolytic viral immunotherapy company, but the filings cluster on payloads: IL-12 paired with soluble PD-1, IL-12 paired with a TGF-beta inhibitor, CD47 and SIRP-alpha inhibition. The vector is the platform. The claimed inventions are increasingly about what rides inside it and which combinations are covered.
That is a defensible position at eleven families precisely because it is narrow. Three grants are live now. Eight more are in the pipeline with the first close. And thirty-two months of filings sit unpublished behind the raise, which is exactly where a company that has been filing steadily since 2018 would be expected to have kept working.
Does a small estate hold in a crowded class?
Three things separate a narrow portfolio that holds from one that merely exists. None of them settles the question alone. Read them together, and note that two can be checked from public records today.
Count without shape
Eleven families in A61K and C12N with no distinguishing evidence is difficult to assess. The portfolio would need reading claim by claim.
What the next two years will show
Do the eight pending families claim payload combinations, or delivery methods, or both?
How much of the thirty-two month publication gap will resolve into new families rather than continuations?
Does the second inventor node, Stephen Howard Thorne, appear on the granted three or the pending eight?
Do the non-US filings in Taiwan, Israel and Korea track particular manufacturing or clinical geographies?
Following those four would tell you whether the estate is a platform with options attached or a set of specific combination claims that stand or fall individually.
Common questions
How many patents does KaliVir Immunotherapeutics have?
KaliVir Immunotherapeutics holds 11 patent families as reviewed in 2026-09: 3 granted and 8 published and pending.
How many of KaliVir Immunotherapeutics's patents are granted?
3 of the 11 families are granted, or 27 percent. The remaining 8 are published and still under examination.
What technology do KaliVir Immunotherapeutics's patents cover?
KaliVir Immunotherapeutics's claims cluster in medicinal preparations (A61K), enzymes, cells and genetic engineering (C12N) and therapeutic activity (A61P). Recent filing titles include "compositions of cd47/sirp-alpha immune checkpoint inhibitors and uses thereof" and "nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof".
Where has KaliVir Immunotherapeutics filed patents?
KaliVir Immunotherapeutics's families appear in 7 patent offices: Australia, Canada, Europe, Israel, South Korea and Taiwan.
Which companies file patents in the same areas as KaliVir Immunotherapeutics?
The same CPC groups drew University of California, Jiangnan University, Zhejiang University and Huazhong Agricultural University over the last five years. Shared classification indicates a common technology field rather than direct competition.
Who cites KaliVir Immunotherapeutics's patents?
Patent records from Zhengzhou University, Calidi Biotherapeutics Nevada, Pfizer and Genelux cite KaliVir Immunotherapeutics's filings. A citation indicates a reference to the work, not evidence of commercial use.
Who invented KaliVir Immunotherapeutics's patents?
20 inventors are named across the portfolio. The most frequently named is Mingrui Zhang. Inventor names do not establish ownership, which is determined by assignment records.
GET IN TOUCH NOW!
OR SCHEDULE A MEETING
